Medpace Acquires Pharma Brains AG
Cincinnati, OH-November 2, 2009
Medpace has entered into a purchase agreement to acquire Pharma Brains AG, an oncology focused CRO based in Basel, Switzerland.
Pharma Brains is led by Dr. Marc Salzberg, President and CEO, a research professional with extensive experience in oncology Phase I-IV studies as well as drug development and regulatory affairs.
"I am pleased to have Dr. Salzberg joining the group as an integral leader beginning with the integration and going forward as the VP of Oncology, Europe and General Manager, Switzerland," said Dr. August Troendle, President and CEO, Medpace. "Marc Salzberg is a distinguished professional in European drug development and brings 17 years of industry and leadership experience to Medpace."
The integration of Pharma Brains operations will begin immediately with the intent of completing the merger by the end of 2009.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
